DNAI · BiobadamexAI · Biologic Therapy Management

Biobadamex therapy—
eligibility, dosing, and monitoring in one place.

Indication verification, dosing optimization, and monitoring schedules for Biobadamex in rheumatoid arthritis — grounded in Dr. Erick Zamora's actual Biobadamex prescribing practice.

Request clinical access Read the brief
Proof of concept · In clinical evaluation · Dr. Erick Zamora
BiobadamexAI · Gestión Terapéutica · Dr. Zamora En uso

Evaluación de elegibilidad

Patricia S. · 54 años · F · AR moderada-severa Respuesta inadecuada a MTX 20 mg/sem por 6 meses. DAS28 4.9. Candidata a biológico. Sin biológico previo.

Criterios de elegibilidad

AR activa (DAS28 > 3.2) · Falla MTX ≥ 6 meses · Sin infección activa · PPD negativo

Laboratorio

DAS28

4.9

PPD

Negativo

Hep B/C

Negativo

Rx tórax

Sin lesiones

Plan terapéutico Biobadamex

Elegible · Confirmado Todos los criterios de indicación cumplidos AR activa con falla DMARD convencional. Screening de infecciones negativo. Sin contraindicaciones activas. Proceder a inicio.
Dosificación Biobadamex 40 mg SC c/2 semanas + MTX Peso 68 kg. Dosis estándar 40 mg SC. Comedicación con MTX aumenta respuesta y reduce inmunogenicidad. Continuar MTX 15 mg/sem.
Monitoreo Primer control a las 12 semanas DAS28 + biometría hemática + función hepática a las 12 semanas. Decisión de respuesta EULAR a las 16 semanas.

Inicio de tratamiento

Primera aplicación: consulta supervisada para reacción de infusión

Auto-aplicación a partir de 2da dosis si tolerancia confirmada

Refrigeración 2-8°C, dejar 30 min a temperatura ambiente antes de inyectar

Registro de sitios de rotación: abdomen, muslos alternando

"Managing Biobadamex without a system means you're holding the eligibility criteria, dosing tables, and monitoring schedule in your head. BiobadamexAI holds it for me."

Dr. Erick Zamora - Rheumatologist · Primary operator

7 of 7 products
in the DNAI
proof stack

Biobadamex eligibility, dosing, and monitoring are three separate checklists — none of them automatic.

Eligibility verification

Pre-biologic screening is multi-step and easy to miss.

TB screening, hepatitis serology, chest X-ray, infection history, prior DMARD failure documentation. BiobadamexAI generates the complete pre-biologic checklist and verifies it against the current clinical record.

Dosing complexity

Weight, renal function, and comedication affect the dosing calculation.

Biobadamex dose is weight-adjusted with renal modification thresholds. Comedication with MTX changes the monitoring interval. BiobadamexAI calculates the right dose for the patient in front of you.

Monitoring burden

Monitoring schedules run for the full duration of therapy.

Labs, infection surveillance, injection site reactions, reactivation screening. BiobadamexAI generates and tracks the monitoring schedule for each patient on Biobadamex.

How BiobadamexAI works.

01

Verify eligibility from the clinical record.

Enter current disease activity, prior DMARD history, comorbidities, and screening results. BiobadamexAI checks against the full Biobadamex indication criteria — EULAR and Mexican COFEPRIS requirements — and flags any missing elements.

02

Calculate the dose and generate the prescription plan.

Weight-adjusted dose, injection frequency, MTX comedication protocol, injection site rotation instructions, first-dose supervision requirements. The complete prescribing plan in one output.

03

Generate and track the monitoring schedule.

Labs at 4, 8, 12, and 24 weeks. Infection surveillance intervals. Reactivation screening calendar. Response assessment at 12 and 24 weeks with DAS28 and EULAR criteria. The schedule follows the patient for the duration of therapy.

Clinical capabilities

What BiobadamexAI manages.

Current capabilities

  • Biobadamex eligibility verification against EULAR and COFEPRIS criteria
  • Pre-biologic screening checklist: TB, hepatitis, chest X-ray, infection history
  • Weight-adjusted dosing with renal function modification
  • MTX comedication protocol and dose optimization
  • Injection site rotation tracking and patient instructions
  • Monitoring schedule: labs, infection surveillance, response assessment
  • EULAR response evaluation at 12 and 24 weeks
  • Adverse event flags: injection reactions, infection signals, hepatotoxicity

Access status

Proof of concept in active clinical evaluation.

BiobadamexAI is in clinical evaluation by Dr. Erick Zamora. Access available to rheumatologists prescribing Biobadamex who want systematic eligibility verification and monitoring management.

Request clinical access Read the DNAI brief first

Part of the DNAI proof stack

BiobadamexAI LES AI RheumaAI RheumaScore ORVS Beach Science / clawRxiv STORM

Common questions.

Is Biobadamex the same as adalimumab?

Biobadamex is an adalimumab biosimilar approved in Mexico. BiobadamexAI is built specifically for Biobadamex using Dr. Erick's prescribing experience with the molecule and Mexican regulatory requirements (COFEPRIS). The clinical protocols differ from reference adalimumab in some monitoring specifics.

Does it handle the full patient journey?

Yes. From eligibility verification before the first dose, through dosing and first-dose supervision, to the monitoring schedule over the full therapy duration. BiobadamexAI covers the complete Biobadamex patient lifecycle.

What happens if a patient fails Biobadamex?

BiobadamexAI flags inadequate response at the 12-week and 24-week assessment points. For failure, it integrates with STORM to model the next treatment option — the two products are designed to work together in sequence.

Does it work for other anti-TNF biologics?

The current version is Biobadamex-specific. The eligibility and monitoring frameworks are calibrated to Dr. Erick's experience with this molecule. Anti-TNF class management more broadly is on the roadmap as BiobadamexAI data accumulates.